Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (THTX)
NASDAQ:THTX
Holding THTX?
Track your performance easily
THTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $2.58
Previous Close$1.21
Volume6.48K
Average Volume (3M)36.32K
Market Cap
$55.70M
Enterprise Value$74.67M
Total Cash (Recent Filing)$38.86M
Total Debt (Recent Filing)$57.83M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 20, 2025EPS Estimate
$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding45,980,019
10 Day Avg. Volume28,010
30 Day Avg. Volume36,317
Standard Deviation0.28
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.84
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)3.10
P/FCF Ratio2.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit1.20
Enterprise Value/Ebitda1.60
Forecast
1Y Price Target
$3.80Price Target Upside214.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®Bulls Say, Bears Say
Bulls Say
Financial Performance2Q24 total revenue of $22M from sales of EGRIFTA SV and TROGARZO exceeded our estimate of $19.52M and consensus of $21.73M.
ProfitabilityTHTX reports a positive net income for the first time, marking the beginning of sustainable profitability for the company.
Revenue GrowthEGRIFTA SV remains the key revenue driver, demonstrating a 26.6% year-over-year increase.
Bears Say
Competitive PressuresTROGARZO sales decreased 22.9% year-over-year due to a loss of market share secondary to competitive pressures.
Operational ChallengesThe stock is facing near-term headwinds until the full impact of the manufacturing pause on the key revenue driving asset EGRIFTA SV is confirmed.
Supply Chain RisksThere is a risk of a temporary supply disruption for EGRIFTA SV due to an unexpected voluntary shutdown of the contract manufacturer's facility following an FDA inspection.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
25.16% Other Institutional Investors
74.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
THTX FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was $1.08 and its highest was $2.58 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Currently, no data Available
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Feb 20, 2025 which is in 61 days.
How were Theratechnologies Inc’s earnings last quarter?
Theratechnologies Inc released its earnings results on Oct 10, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03.
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Undervalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is $0.05.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Theratechnologies Inc reported an EPS of $0.06 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went up 3.279%.
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in THTX
---
Theratechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.80 (214.05% Upside)
$3.80 (214.05% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 12.9%
Last 30 Days ▼ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.
---
THTX Earnings Call
Q3 2024
0:00 / 0:00
---
THTX Stock 12 Month Forecast
Average Price Target
$3.80
▲(214.05% Upside)
Technical Analysis
Best Analysts Covering THTX
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+2.38%
upgraded a buy rating 2 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +2.38% per trade.
---